RS-2026-25503246

Development of a First-in-Class MSLN x GAS6 Trap Bispecific ADC Candidate for Pancreatic Cancer: Overcoming Antigen Shedding and Remodeling Tumor Microenvironment

Seoul National University

SNU MEDICINE
Seoul National University College of Medicine

ONCOLOGY | **Hit**

Product Type	Antibody
Indication	PDAC (Pancreatic ductal adenocarcinoma)
Target	MSLN & TAM
MoA(Mechanism of Action)	A MSLN × GAS6 Trap bispecific ADC selectively binds membrane-bound MSLN on tumor cells and kill them with a cytotoxic payload. At the same time, the fused GAS6 trap captures TME-derived GAS6, blocking TAM receptor mediated survival, acquired resistance, efferocytosis, and immune suppression, thereby promoting cold-to-hot TME remodeling. 
Competitiveness	**1) Shedding-resistant antibody** Region III-targeting MSLN antibody preferentially binds membrane-bound MSLN over soluble MSLN, reducing antigen shedding-related decoy/sink effects. **2) GAS6 trap fusion** GAS6 trap fusion directly sequesters TME-derived GAS6, unlike conventional ADCs that mainly rely on payload-mediated cytotoxicity. Provides triple action: tumor cell killing, resistance blockade, and immune TME remodeling.
Development Stage	Hit
Route of Administration	Intravenous administration, every 3 weeks (Q3W)